WALTHAM, Mass.–(BUSINESS WIRE)–Oct. 16, 2018– Kala Pharmaceuticals, Inc. (Kala) (NASDAQ:KALA), today announced that it has submitted a New Drug Application (NDA) to the United States Food and Drug Administration (FDA) for KPI-121 0.25%, a topical…Original Article
Kala Pharmaceuticals Submits New Drug Application to U.S. Food and Drug Administration for KPI-121 0.25% for Dry Eye Disease
